Analysts Expect a 10% Increase for IYY
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 02 2025
0mins
Should l Buy EXEL?
Source: NASDAQ.COM
ETF Analysis: The iShares Dow Jones U.S. ETF (IYY) has an implied analyst target price of $178.58, indicating a potential upside of 9.53% from its current trading price of $163.04.
Notable Holdings: Key underlying holdings with significant upside potential include First Horizon Corp (10.63% upside), Exelixis Inc (10.12% upside), and Evercore Inc (10.06% upside) based on their respective analyst target prices.
Analyst Target Justification: The article raises questions about whether analysts' target prices are justified or overly optimistic, suggesting that high targets may lead to downgrades if they do not align with current market conditions.
Further Research Needed: Investors are encouraged to conduct additional research to assess the validity of the analysts' targets in light of recent developments in the companies and their industries.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy EXEL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on EXEL
Wall Street analysts forecast EXEL stock price to fall
16 Analyst Rating
7 Buy
8 Hold
1 Sell
Moderate Buy
Current: 44.380
Low
30.00
Averages
44.09
High
52.00
Current: 44.380
Low
30.00
Averages
44.09
High
52.00
About EXEL
Exelixis, Inc. is an oncology company. The Company has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. It is also advancing and evolving its product pipeline portfolio, including its lead investigational asset, zanzalintinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma, for previously treated hepatocellular carcinoma and for previously treated, radioactive iodine-refractory differentiated thyroid cancer, and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer. The Company's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved the treatment of hypertension in Japan.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Three Biotech Companies Worth Watching
- Krystal Biotech's Breakthrough: In 2023, Krystal Biotech received approval for Vyjuvek, a gene therapy for Dystrophic Epidermolysis Bullosa, achieving $389.1 million in revenue, a 34% year-over-year increase, indicating strong market potential in rare diseases.
- Madrigal Pharmaceuticals' FDA Approval: In 2024, Madrigal gained FDA approval for Rezdiffra, the first drug for metabolic dysfunction-associated steatohepatitis, with 2025 revenue reaching $958.4 million, a staggering 432% increase, showcasing robust growth in an emerging market.
- Exelixis' Oncology Innovations: Exelixis' Cabometyx remains the leading treatment for liver and kidney cancers, with no generic competition expected until 2030, while the company plans to launch several next-gen cancer therapies in the next five years, further solidifying its market position.
- Significant Market Potential: The combination of innovation and market demand in these three companies suggests that their stocks could yield substantial returns in the future, particularly in the ongoing developments within rare diseases and oncology.
See More
Three Biotech Stocks Worth Watching
- Krystal Biotech's Breakthrough: Focused on rare diseases, Krystal Biotech received approval for Vyjuvek, a gene therapy for Dystrophic Epidermolysis Bullosa, achieving $389.1 million in revenue in 2023, a 34% year-over-year increase, indicating strong market performance.
- Madrigal Pharmaceuticals' Market Potential: Madrigal's Rezdiffra, approved by the FDA in 2024 as the first treatment for metabolic dysfunction-associated steatohepatitis, generated $958.4 million in revenue in 2025, a staggering 432% increase, showcasing its potential in a large patient market.
- Exelixis' Innovative Drugs: Exelixis' Cabometyx, a leading treatment for liver and kidney cancers, is expected to face no generic competition until 2030, while its development of next-gen cancer therapies could further drive growth in the coming years.
- Competitive Advantages: These three companies demonstrate significant market potential and innovation capabilities, with Krystal Biotech and Madrigal expanding their product lines to enhance market share, while Exelixis maintains a strong position in oncology through robust financial performance and R&D efforts.
See More
Exelixis Market Trends Analysis
- Market Insights: In the Motley Fool Scoreboard episode, expert analysts discuss Exelixis's market dynamics, providing deep insights into investment opportunities that help investors grasp future trends.
- Investment Opportunity Assessment: The episode emphasizes Exelixis's potential in the biopharmaceutical sector, particularly in new drug development and market expansion, which could yield substantial returns for investors.
- Stock Price Reference: The stock price mentioned in the episode is from February 11, 2026, reflecting Exelixis's market performance at that time, providing historical context for investors.
- Video Release Information: This video was published on March 31, 2026, aimed at providing viewers with the latest market analysis and investment advice, enhancing investor understanding of Exelixis.
See More
Exelixis Investment Insights from Motley Fool
- Market Trend Analysis: In the latest Motley Fool video, analysts discuss market trends for Exelixis, noting that while the company did not make the list of the top 10 recommended stocks, it still presents potential investment opportunities.
- Return Comparison: The average return of Stock Advisor stands at 880%, significantly outperforming the S&P 500's 178%, indicating that even though Exelixis is not recommended, investors should still monitor its market performance.
- Historical Performance Review: The video highlights that Netflix and Nvidia achieved investment returns of 501,381% and 1,012,581% respectively after being recommended, underscoring the importance of selecting the right stocks.
- Investor Community Building: Motley Fool encourages investors to join its community for the latest investment advice and market analysis, suggesting that while Exelixis is not on the recommended list, more information can still be obtained through the community.
See More
High-Quality Healthcare Stocks Under $50
- Pfizer's Outlook: Pfizer's stock trades around $27 with a P/E ratio of 9, significantly below the healthcare industry's average of 17.8; with a robust pipeline in oncology and chronic weight management, the company is poised for substantial clinical advancements over the next five years, likely improving financial performance and boosting sales.
- Novo Nordisk's Market Potential: Priced at approximately $39 with a P/E ratio of 10.4, Novo Nordisk stands to benefit from the rapidly expanding weight-loss market, positioning itself as a leader in anti-obesity products, which could yield significant returns for patient investors over the next five to ten years.
- Exelixis' Innovative Growth: Exelixis, trading at around $41, has carved a niche in oncology with its Cabometyx therapy, and is expected to report ongoing revenue and earnings growth while developing new drugs to address the patent cliff in 2030, showcasing strong market prospects.
- Attractiveness of Oncology Market: Exelixis's zanzalintinib has shown effectiveness in treating metastatic colorectal cancer, which is the second leading cause of cancer death globally; given this market's potential, the company is likely to enhance its competitiveness through new product transformations.
See More
Amazon Launches Ultra-Fast Delivery Service
- Logistics War Escalation: Amazon has launched one-hour and three-hour delivery services across over 2,000 U.S. cities, covering 90,000 high-frequency items, aiming to boost shopping frequency through new specialized workstations, although Prime members must now pay a $9.99 surcharge, marking a shift from Amazon's traditional 'free shipping' model to a high-margin service.
- Fee Structure Adjustment: The new tiered fee structure ($9.99 for one-hour delivery and $4.99 for three-hour delivery) indicates Amazon's strategy to cover high variable costs of last-mile logistics while striving to maintain overall Prime margins, reflecting its pursuit of profitability amid competition.
- Operational Efficiency Improvement: By deploying predictive AI to pre-position inventory in smaller urban facilities, Amazon is transforming its same-day fulfillment hubs into high-velocity local storefronts, thereby accelerating delivery speeds and enhancing market competitiveness.
- Market Share Competition: This service launch is not only a direct response to Walmart's 'Express Delivery' network but also has the potential to further solidify Amazon's leadership in the e-commerce market by increasing customer loyalty and shopping frequency.
See More
Three Biotech Companies Worth Watching
- Krystal Biotech's Breakthrough: In 2023, Krystal Biotech received approval for Vyjuvek, a gene therapy for Dystrophic Epidermolysis Bullosa, achieving $389.1 million in revenue, a 34% year-over-year increase, indicating strong market potential in rare diseases.
- Madrigal Pharmaceuticals' FDA Approval: In 2024, Madrigal gained FDA approval for Rezdiffra, the first drug for metabolic dysfunction-associated steatohepatitis, with 2025 revenue reaching $958.4 million, a staggering 432% increase, showcasing robust growth in an emerging market.
- Exelixis' Oncology Innovations: Exelixis' Cabometyx remains the leading treatment for liver and kidney cancers, with no generic competition expected until 2030, while the company plans to launch several next-gen cancer therapies in the next five years, further solidifying its market position.
- Significant Market Potential: The combination of innovation and market demand in these three companies suggests that their stocks could yield substantial returns in the future, particularly in the ongoing developments within rare diseases and oncology.
See More
Three Biotech Stocks Worth Watching
- Krystal Biotech's Breakthrough: Focused on rare diseases, Krystal Biotech received approval for Vyjuvek, a gene therapy for Dystrophic Epidermolysis Bullosa, achieving $389.1 million in revenue in 2023, a 34% year-over-year increase, indicating strong market performance.
- Madrigal Pharmaceuticals' Market Potential: Madrigal's Rezdiffra, approved by the FDA in 2024 as the first treatment for metabolic dysfunction-associated steatohepatitis, generated $958.4 million in revenue in 2025, a staggering 432% increase, showcasing its potential in a large patient market.
- Exelixis' Innovative Drugs: Exelixis' Cabometyx, a leading treatment for liver and kidney cancers, is expected to face no generic competition until 2030, while its development of next-gen cancer therapies could further drive growth in the coming years.
- Competitive Advantages: These three companies demonstrate significant market potential and innovation capabilities, with Krystal Biotech and Madrigal expanding their product lines to enhance market share, while Exelixis maintains a strong position in oncology through robust financial performance and R&D efforts.
See More
Exelixis Market Trends Analysis
- Market Insights: In the Motley Fool Scoreboard episode, expert analysts discuss Exelixis's market dynamics, providing deep insights into investment opportunities that help investors grasp future trends.
- Investment Opportunity Assessment: The episode emphasizes Exelixis's potential in the biopharmaceutical sector, particularly in new drug development and market expansion, which could yield substantial returns for investors.
- Stock Price Reference: The stock price mentioned in the episode is from February 11, 2026, reflecting Exelixis's market performance at that time, providing historical context for investors.
- Video Release Information: This video was published on March 31, 2026, aimed at providing viewers with the latest market analysis and investment advice, enhancing investor understanding of Exelixis.
See More
Exelixis Investment Insights from Motley Fool
- Market Trend Analysis: In the latest Motley Fool video, analysts discuss market trends for Exelixis, noting that while the company did not make the list of the top 10 recommended stocks, it still presents potential investment opportunities.
- Return Comparison: The average return of Stock Advisor stands at 880%, significantly outperforming the S&P 500's 178%, indicating that even though Exelixis is not recommended, investors should still monitor its market performance.
- Historical Performance Review: The video highlights that Netflix and Nvidia achieved investment returns of 501,381% and 1,012,581% respectively after being recommended, underscoring the importance of selecting the right stocks.
- Investor Community Building: Motley Fool encourages investors to join its community for the latest investment advice and market analysis, suggesting that while Exelixis is not on the recommended list, more information can still be obtained through the community.
See More
High-Quality Healthcare Stocks Under $50
- Pfizer's Outlook: Pfizer's stock trades around $27 with a P/E ratio of 9, significantly below the healthcare industry's average of 17.8; with a robust pipeline in oncology and chronic weight management, the company is poised for substantial clinical advancements over the next five years, likely improving financial performance and boosting sales.
- Novo Nordisk's Market Potential: Priced at approximately $39 with a P/E ratio of 10.4, Novo Nordisk stands to benefit from the rapidly expanding weight-loss market, positioning itself as a leader in anti-obesity products, which could yield significant returns for patient investors over the next five to ten years.
- Exelixis' Innovative Growth: Exelixis, trading at around $41, has carved a niche in oncology with its Cabometyx therapy, and is expected to report ongoing revenue and earnings growth while developing new drugs to address the patent cliff in 2030, showcasing strong market prospects.
- Attractiveness of Oncology Market: Exelixis's zanzalintinib has shown effectiveness in treating metastatic colorectal cancer, which is the second leading cause of cancer death globally; given this market's potential, the company is likely to enhance its competitiveness through new product transformations.
See More
Amazon Launches Ultra-Fast Delivery Service
- Logistics War Escalation: Amazon has launched one-hour and three-hour delivery services across over 2,000 U.S. cities, covering 90,000 high-frequency items, aiming to boost shopping frequency through new specialized workstations, although Prime members must now pay a $9.99 surcharge, marking a shift from Amazon's traditional 'free shipping' model to a high-margin service.
- Fee Structure Adjustment: The new tiered fee structure ($9.99 for one-hour delivery and $4.99 for three-hour delivery) indicates Amazon's strategy to cover high variable costs of last-mile logistics while striving to maintain overall Prime margins, reflecting its pursuit of profitability amid competition.
- Operational Efficiency Improvement: By deploying predictive AI to pre-position inventory in smaller urban facilities, Amazon is transforming its same-day fulfillment hubs into high-velocity local storefronts, thereby accelerating delivery speeds and enhancing market competitiveness.
- Market Share Competition: This service launch is not only a direct response to Walmart's 'Express Delivery' network but also has the potential to further solidify Amazon's leadership in the e-commerce market by increasing customer loyalty and shopping frequency.
See More
